Profile data is unavailable for this security.
About the company
Paxman AB (publ) is a Sweden-based developer of scalp cooling technology. The cooling system aims to reduce the risk of hair loss connected with cytostatic treatment of cancer. The Company offers a stand-alone, mobile electric cooling unit, which markets under the name Paxman Scalp Cooler, which is a liquid-based cooling system that cools down the patients scalp through the silicone hat. The product has two versions - for one or two patients to be cooled at once. Each device contains a built-in touch screen with a menu-controlled graphic user interface to monitor the process. The lightweight system enables patient to participate in other activities. The Company’s primary markets are Great Britain, Scandinavian countries, the Netherlands, Belgium and Australia.
- Revenue in SEK (TTM)238.86m
- Net income in SEK28.64m
- Incorporated2016
- Employees102.00
- LocationPaxman AB (publ)Pirgatan 13KARLSHAMN 374 35SwedenSWE
- Websitehttps://www.paxman.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Senzime AB (publ) | 55.29m | -131.46m | 708.35m | 52.00 | -- | 2.62 | -- | 12.81 | -1.09 | -1.09 | 0.4595 | 2.38 | 0.1533 | 1.57 | 4.91 | -- | -36.44 | -35.69 | -39.12 | -38.00 | 33.27 | -20.59 | -237.75 | -558.68 | 2.62 | -- | 0.0739 | -- | 154.77 | 61.90 | -1.09 | -- | -3.69 | -- |
| ADDvise Group AB (publ) | 1.63bn | 114.40m | 795.28m | 643.00 | 20.89 | 3.15 | 3.78 | 0.489 | 0.5935 | 0.5935 | 8.38 | 3.93 | 0.565 | 8.37 | 5.77 | 2,606,250.00 | 3.98 | 3.72 | 4.82 | 4.77 | 42.07 | 48.95 | 7.04 | 5.89 | 1.40 | 2.35 | 0.6969 | 0.9405 | 44.30 | 38.62 | 27.62 | -- | 30.35 | -- |
| C Rad AB | 497.02m | 53.43m | 937.77m | 94.00 | 18.01 | 3.18 | 14.98 | 1.89 | 1.58 | 1.58 | 14.72 | 8.96 | 1.23 | 5.04 | 2.72 | 5,712,816.00 | 13.25 | 5.09 | 19.16 | 7.02 | 46.30 | 43.12 | 10.81 | 4.86 | 2.32 | -- | 0.0049 | 0.00 | 40.92 | 17.44 | 375.05 | 10.89 | 33.69 | -- |
| Optomed Oyj | 169.98m | -56.07m | 972.00m | 110.00 | -- | 3.07 | -- | 5.72 | -0.2761 | -0.2761 | 0.8501 | 1.40 | 0.4762 | 1.69 | 4.10 | 129,035.10 | -15.71 | -12.95 | -19.11 | -15.90 | 67.77 | 65.69 | -32.98 | -27.84 | 2.67 | -- | 0.1424 | -- | 3.00 | 3.47 | 18.84 | -- | 7.26 | -- |
| Bactiguard Holding AB | 254.96m | -56.11m | 1.13bn | 163.00 | -- | 3.88 | -- | 4.43 | -1.60 | -1.60 | 7.28 | 9.37 | 0.3706 | 3.84 | 7.60 | 1,174,917.00 | -8.16 | -7.56 | -11.32 | -8.81 | 47.53 | 47.91 | -22.01 | -26.28 | 0.5898 | -2.72 | 0.4175 | -- | -11.96 | 6.46 | -161.71 | -- | 8.43 | -- |
| BioPorto A/S | 52.41m | -77.48m | 1.17bn | 33.00 | -- | 7.18 | -- | 22.25 | -0.1397 | -0.1397 | 0.0941 | 0.244 | 0.2777 | 3.23 | 9.02 | 1,091,290.00 | -41.06 | -71.10 | -51.28 | -96.55 | 71.13 | 63.38 | -147.84 | -239.22 | 5.16 | -- | 0.0517 | -- | 6.87 | 3.54 | 25.81 | -- | -51.56 | -- |
| Sedana Medical AB (publ) | 174.14m | -57.24m | 1.28bn | 78.00 | -- | 1.34 | -- | 7.34 | -0.5763 | -0.5763 | 1.75 | 9.56 | 0.1697 | 1.16 | 10.14 | 2,204,317.00 | -5.58 | -5.77 | -5.84 | -6.08 | 70.60 | 64.06 | -32.87 | -36.13 | 6.02 | -30.48 | 0.0076 | -- | 25.23 | 21.59 | 18.90 | -- | 42.12 | -- |
| Paxman AB (publ) | 238.86m | 28.64m | 1.35bn | 102.00 | 47.23 | 9.26 | 28.76 | 5.65 | 1.50 | 1.50 | 12.54 | 7.67 | 1.31 | 2.74 | 6.56 | 2,624,791.00 | 15.66 | -5.08 | 20.74 | -7.76 | 70.27 | 69.38 | 11.99 | -5.07 | 1.98 | 12.73 | 0.0838 | -- | 43.99 | 29.35 | 180.69 | -- | 6.26 | -- |
| Nordhealth As | 477.01m | -107.78m | 1.64bn | 355.00 | -- | 3.17 | 97.36 | 3.43 | -1.41 | -1.41 | 6.20 | 11.64 | 0.4329 | -- | 6.73 | 1,228,757.00 | -9.78 | -- | -11.11 | -- | 85.82 | -- | -22.59 | -- | -- | -- | 0.00 | -- | 18.60 | -- | 21.96 | -- | -- | -- |
| Genovis AB | 127.02m | 17.25m | 1.75bn | 37.00 | 101.52 | 8.43 | 60.25 | 13.79 | 0.2635 | 0.2635 | 1.94 | 3.17 | 0.4938 | -- | -- | 3,432,973.00 | 6.71 | 18.56 | 7.21 | 21.45 | 64.41 | 65.51 | 13.58 | 23.88 | -- | 697.00 | 0.2718 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Stille AB | 487.43m | 50.86m | 1.91bn | 151.00 | 33.66 | 2.85 | 25.51 | 3.93 | 6.33 | 6.33 | 60.94 | 74.85 | 0.6978 | 2.10 | 8.49 | 4,598,368.00 | 7.28 | 7.03 | 8.70 | 8.19 | 49.17 | 43.93 | 10.43 | 9.85 | 1.12 | 7.41 | 0.00 | 21.98 | 19.70 | 16.78 | -2.48 | 5.34 | 23.62 | -- |
Data as of Nov 12 2024. Currency figures normalised to Paxman AB (publ)'s reporting currency: Swedish Krona SEK
14.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Bank of New York Mellon Corp. (Investment Management)as of 29 Dec 2023 | 1.03m | 5.43% |
| Alcur Fonder ABas of 29 Dec 2023 | 674.83k | 3.55% |
| L�nsf�rs�kringar Fondf�rvaltning ABas of 29 Dec 2023 | 585.00k | 3.08% |
| Andra AP-fondenas of 29 Dec 2023 | 456.62k | 2.40% |
| E. �hman J :or Fonder ABas of 31 May 2024 | 35.88k | 0.19% |
| AIFM Capital ABas of 30 Jun 2024 | 4.61k | 0.02% |
| FCG Fonder ABas of 30 Sep 2024 | 4.10k | 0.02% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
